On November 5, 2025, Eli Lilly and Company highlighted its expanding commitment to the Chinese market at the 8th China International Import Expo (CIIE) in Shanghai. The company showcased several key products, including its successful diabetes and weight-loss drug Tirzepatide and the Alzheimer's treatment Donanemab. It also presented drugs awaiting Chinese approval, such as Imlunestrant for breast cancer and Mirikizumab for inflammatory bowel disease. The centerpiece of Lilly's announcement was the establishment of a new Shanghai Innovation Incubator, its second in China after a similar launch in Beijing in March 2025. This move is part of a broader 'full-industry-chain localization' strategy, which includes significant investments in local research and development, clinical trials, and manufacturing capacity. The company aims to accelerate the introduction and deep integration of its innovative medicines within the 'Healthy China' initiative.